D-0316 Shows Encouraging Efficacy in EGFR T790M+ NSCLC Subsets
Treatment with D-0316 demonstrated encouraging clinical activity in select patients with EGFR T790M-positive non–small cell lung cancer who progressed on prior therapy.
Related Articles
Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain
Experts discuss the FDA’s call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.
Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC
Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.
Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates
Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
European Medicines Agency Grants Orphan Drug Designation to Annamycin in AML
The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.
FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection
The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.
Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer
Anne Favret, MD discusses the FDA approval of capivasertib in combination with fulvestrant for HR-positive, HER2-negative breast cancer.
Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
Updated phase 1 findings with botensilimab/balstilimab in MSS/pMMR mCRC show that the regimen elicited respective 12- and 18-month OS rates of 71% and 62%.
FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer
The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.